Intra-Cellular Therapies, Inc.
ITCIDrugs in Pipeline
14
Phase 3 Programs
7
Upcoming Catalysts
6
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
6 upcoming, 0 past
Lumateperone high dose
Irritability Associated With Autism Spectrum Disorder
ITI-007
Schizophrenia
ITI-007 (Lumateperone)
Bipolar Depression
Lumateperone
Major Depressive Disorder
Lumateperone low dose
Irritability Associated With Autism Spectrum Disorder
Lumateperone 42 mg
Schizophrenia
Lumateperone (ITI-007)
Bipolar Depression
Risperidone
Schizophrenia
ITI-214
Heart Failure, Systolic
ITI-1284 20 mg
Generalized Anxiety Disorder
ITI-1284
Agitation Associated With Alzheimer's Dementia
Lenrispodun
Parkinson Disease
ITI-1284 10 mg
Generalized Anxiety Disorder
Caplyta
Borderline Personality Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lumateperone high dose | Phase 3 | Irritability Associated With Autism Spectrum Disorder | - | - |
ITI-007 | Phase 3 | Schizophrenia | - | - |
ITI-007 (Lumateperone) | Phase 3 | Bipolar Depression | - | - |
Lumateperone | Phase 3 | Major Depressive Disorder | - | - |
Lumateperone low dose | Phase 3 | Irritability Associated With Autism Spectrum Disorder | - | - |
Lumateperone 42 mg | Phase 3 | Schizophrenia | - | - |
Lumateperone (ITI-007) | Phase 3 | Bipolar Depression | - | - |
Risperidone | Phase 2 | Schizophrenia | - | - |
ITI-214 | Phase 2 | Heart Failure, Systolic | - | - |
ITI-1284 20 mg | Phase 2 | Generalized Anxiety Disorder | - | - |
ITI-1284 | Phase 2 | Agitation Associated With Alzheimer's Dementia | - | - |
Lenrispodun | Phase 2 | Parkinson Disease | - | - |
ITI-1284 10 mg | Phase 2 | Generalized Anxiety Disorder | - | - |
Caplyta | Phase 2 | Borderline Personality Disorder | - | - |
Bipolar Depression
3 drugs in this indication
Irritability Associated With Autism Spectrum Disorder
2 drugs in this indication
Generalized Anxiety Disorder
2 drugs in this indication
Schizophrenia
2 drugs in this indication
Major Depressive Disorder
1 drug in this indication
Heart Failure, Systolic
1 drug in this indication
Agitation Associated With Alzheimer's Dementia
1 drug in this indication
Parkinson Disease
1 drug in this indication
Psychosis Associated With Alzheimer's Disease
1 drug in this indication
Magnesium transport
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Intra-Cellular Therapies, Inc.'s drug pipeline?→
CatalystAlert tracks 14 drug candidates in Intra-Cellular Therapies, Inc.'s (ITCI) pipeline across Phase 3, Phase 2. Its lead program is Lumateperone high dose (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Intra-Cellular Therapies, Inc.'s next FDA catalyst?→
Intra-Cellular Therapies, Inc.'s (ITCI) next tracked catalyst is a Phase 3 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ITCI biotech catalysts?→
Add ITCI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Intra-Cellular Therapies, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.